Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zatolmilast for scopolamine-induced cognitive impairment
NCT03030105Phase 1Completed
- Sponsor
- Tetra Therapeutics
- Start
- Jan 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zatolmilast in Alzheimer's disease (AD) (6 arms), sponsored by Tetra Therapeutics. Primary endpoint: Groton Maze Learning Test. Started Jan 2017; status: completed.
02
Drugs
zatolmilast
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03030105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03030105.